Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live

Zoster Vaccine Live (ZVL) is marketed in the US since 2008, and a non-live adjuvanted Recombinant Zoster Vaccine (RZV) was approved in 2017. Literature suggests that waning of ZVL efficacy may necessitate additional vaccination. The Advisory Committee on Immunization Practices recommended vaccinatio...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Hum Vaccin Immunother
Egile Nagusiak: Curran, Desmond, Patterson, Brandon J., Van Oorschot, Desiree, Buck, Philip O., Carrico, Justin, Hicks, Katherine A., Lee, Bruce, Yawn, Barbara P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2019
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605828/
https://ncbi.nlm.nih.gov/pubmed/30625011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1558689
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak